|
Supporting Research & Clinical Studies
Below are the research references and clinical studies which
validate the
information documented on this website.
1) P.M. Brooks, S.R. Potter and
W.W. Buchanan, "NSAID and Osteoarthritis-- Help or Hindrance,"
J Rheutatol 9 (19820: 3-5.
2) N.M.Newman, R.S.M. Ling, "acetabular
Bone Destruction Related to Non-Steroidal Anti-inflammatory Drugs,"
Lancet 2 (1985):11-13]
3) Shield MJ, Anti-inflammatory
drugs and their effects on cartilage synthesis and renal function. Eur J Rheumatol Inflam 13:7-16, 1993
4) Ronningen H and Langeland N, Indomethacin treatment in
osteoarthritis of the hip joint. Acta Orthop Scand 50:169-74, 1979
5) Solomon L, Drug induced arthropathy and necrosis of the femoral
head. J Bone Joint Surg 55B:246-51, 1973
6) Clinical Gastroenterology
and Hepatology, January 2005; vol 3. David Y. Graham, MD, head,
gastroenterology, Michael DeBakey Medical Center and professor of
medicine, Baylor College of Medicine, Houston
7) Knill-Jones RP, Pearce H, Batten J,
et al. Comparative trial of Nutrizym in chronic pancreatic insufficiency.
Brit Med J 1970;4:21.
8) Balakrishnan V, Hareendran A,
Sukumaran Nair C. Double-blind cross-over trial of an enzyme preparation in
pancreatic steatorrhea. J Asso Phys Ind 1981;29:207-209.
9) Seligman B. Bromelain-an anti-inflammatory agent thrombophlebitis. No
toxicity. Angiology 1962;13:508-510.
10) Felton G. Does Kinin released by
pineapple stem bromelain stimulate production of prostaglandin E1-like
compound. Haw Med J 1976;2:39-47.
11) Mynott TL, Luke RK, Chandler DS.
Oral administration of protease inhibits enterotoxigenic Escherichia coli
receptor activity in piglet small intestine. Gut 1996;38:28-32.
12) Gupta I, Parihar A, Malhotra P, et
al. Effects of Boswellia serrata gum resin in patients with ulcerative
colitis. Eur J Med Res 1997;2(1):37-43.
13) Gupta I, Parihar A, Malhotra P, et
al. Effects of gum resin of Boswellia serrata in patients with chronic
colitis. Planta Med 2001;67(5):391-395.
14) Taussig SJ, Nieper HA. Bromelain:
its use in prevention and treatment of cardiovascular disease, present
status. J IAPM 1979;6:139-151.
15) Giacca S. Clinical experiments with
bromelain in peripheral venous diseases and chronic bronchitic states.
Minerva Med 1965;56:Suppl.104.
16) Nieper HA. Effect of bromelain on
coronary heart disease and angina pectoris. Acta Med Empirica
1978;5:274-278.
17) Nieper HA. Decrease of the
incidence of coronary heart infarct by Mg- and K-orotate and bromelain. Acta
Med Empirica 1977;12:614-618.
18) Masson M. Bromelain in
blunt injuries of the locomotor system. Fortschr Med
1995;113:303-306.
19) Tassman GC,
Zafran JN, Zayon GM. Evaluation of a plant proteolytic
enzyme for the control of inflammation and pain. J Dent
Med 1964;19:73-77.
20) Blonstein JL. Control of
swelling in boxing injuries. Practitioner 1960;185:78.
21) Mojcik C, Shevach E. Adhesion
molecules: a rheumatologic perspective. Arthritis Rheum 1997;40:991–1004.
22) Bodi T. The effects of oral
bromelains on tissue permeability to antibiotics and pain response to
bradykinin: double blind studies on human subjects. Clin Med 1966;73:61–65.
23) Uhlig G, Seifert J. Die Wirkung
proteolytischer Enzyme auf das posttraumatische Syndrom. Fortschritte der
Medizin 1981;15:554–556.
24) Cohen A, Goldman J. Bromelain
therapy in rheumatoid arthritis. Penn Med J 1964;67:27–30.
25) Leipner J, Iten F, Saller R.
Therapy with proteolytic enzymes in rheumatic disorders. Biodrugs
2001;15:779–789.
26) Singer F, Oberleitner H. Drug
therapy of activated arthrosis. On the effectiveness of an enzyme mixture
versus diclofenac. Wien Med Wochenschr 1996;146:55–58.
27) Klein G, Kullich W. Short-term
treatment of painful osteoarthritis of the knee with oral enzymes: a
randomised, double-blind study versus Diclofenac. Clin Drug Invest
2000;19:15–23.
28) Singer F, Singer C, Oberleitner H.
Phlyoenzym versus diclofenac in the treatment of activated osteoarthritis of
the knee. Int J Immunother 2001;17:135–141.
29) Tilwe GH, Beria S, Turakhia NH,
Daftary GV, Schiess W. Efficacy and tolerability of oral enzyme therapy as
compared to diclofenac in active osteoarthritis of the knee joint: an open
randomised controlled clinical trial. Journal of the Association of
Physicians of India. JAPI 2001;49:621.
30) Walker AF, Bundy R, Hicks SM,
Middleton RW. Bromelain reduces mild acute knee pain and improves well being
in a dose dependant fashion in an open study of otherwise healthy adults.
Phytomedicine 2002;9:681–686.
31) Bellamy N, Buchanan W, Goldsmith C,
Campbell J, Stitt L. Validation study of WOMAC: a health status instrument
for measuring clinically important patient relevant outcomes to
anti-rheumatic drug therapy in patients with osteoarthritis of the hip or
knee. Rheumatology 1988;15:1833–1840.
32) Ammon HP. Boswellic acids
(components of frankincense) as the active principle in treatment of chronic
inflammatory diseases [article in German]. Wien Med Wochenschr
2002;152(15-16):373-378.
33) Etzel R. Special extract of Boswellia serrata (H15) in the treatment of
rheumatoid arthritis. Phytomed 1996;3(1):91-94.
34) Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and
tolerability of Boswellia serrata extract in treatment of osteoarthritis of
knee: a randomized double blind placebo controlled trial. Phytomedicine
2003;Jan, 10(1):3-7.
35) Singh GB, Bani S, Singh S. Toxicity and safety evaluation of boswellic
acids. Phytomed 1996;3(1):87-90.
36) Singh GB, Singh S, Bani S. Anti-inflammatory actions of boswellic acids.
Phytomed 1996;3(1):81-85.
37) Chrubasik S, Model A, Black A, et al. A
randomized double-blind pilot study comparing Doloteffin® (Devils Claw
Extract) and Vioxx® in the treatment of low back pain. Rheumatology
2003;42:141-148.
38) Mahomed IM, Ojewole JA. Analgesic,
antiinflammatory and antidiabetic properties of Harpagophytum procumbens DC
(Pedaliaceae) secondary root aqueous extract. Department of Pharmacology,
Faculty of Health Sciences, University of KwaZulu-Natal, Private Bag X54001,
Durban 4000, South Africa.
39) Wegener T, Lupke NP. Treatment of
patients with arthrosis of hip or knee with an aqueous extract of devil's
claw (Harpagophytum procumbens DC.). Phytother Res. Dec2003;17(10):1165-72.
40) Chantre P, Cappelaere A, Leblan D,
Guedon D, Vandermander J, Fournie B. Efficacy and tolerance of Harpagophytum
procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine.
2000 Jun;7(3):177-83.
41) Baghdikian B, Lanhers MC,
Fleurentin J, Ollivier E, Maillard C, Balansard G, Mortier F. An analytical
study, anti-inflammatory and analgesic effects of Harpagophytum procumbens
and Harpagophytum zeyheri. Planta Med. 1997 Apr;63(2):171-6.
42) L. Long, K. Soeken1 and E. Ernst. Herbal medicines for the treatment of
osteoarthritis: a systematic review. Department of Complementary Medicine,
School of Postgraduate Medicine and Health Studies, University of Exeter, 25
Victoria Park Road, Exeter EX2 4NT, UK and University of Maryland School of
Medicine, Complementary Medicine Program, Kernan Hospital Mansion, 2200
Kernan Drive, Baltimore, MD 21207-6697, USA
43) Chrubasik S, Junck H, Breitschwerdt H, et al. Effectiveness of
Harpagophytum extract WS 1531 in the treatment of exacerbation of low back
pain: a randomized, placebo-controlled, double- blind study. Eur J
Anaesthesiol 1999;16(2):118-129.
44) Franci B, Campagna S, Battisti E,
et al. The Efficacy and Safety of Glucosamine Sulfate in the Treatment of
Gonarthritis. Clin Ter. Mar1996;147(3):99-105.
45) Pavelka K, Gatterova J, Olejarova
M, Machacek S, Giacovelli G, Rovati LC. Glucosamine Sulfate Use and Delay of
Progression of Knee Osteoarthritis: A 3-Year, Randomized,
Placebo-Controlled, Double-blind Study. Arch Intern Med.
Oct2002;162(18):2113-23.
46)
Yves RJ,et al. Long-term effects of glucosamine sulphate on
osteoarthritis progression: a randomised, placebo-controlled
clinical trial. Lancet. 2001 Jan 27;357(9252):251-6.
47) Lippiello L, Woodward J, Karpman R,
Hammad TA. In vivo chondroprotection and metabolic synergy of glucosamine
and chondroitin sulfate. Clin Orthop. Dec2000;(381):229-40.
48) Shankland WE 2nd. The Effects of
Glucosamine and Chondroitin Sulfate on Osteoarthritis of the TMJ: A
Preliminary Report of 50 Patients. Cranio. Oct1998;16(4):230-35.
49) McCarty MF. Glucosamine for Wound
Healing. Med Hypotheses. Oct1996;47(4):273-75.
50) Noack W, et al.: Glucosamine sulfate in
osteoarthritis of the knee. Osteoarthritis Cartilage 2:51-9, 1994.
51)
Crolle G and D'este E: Glucosamine sulfate for the management of arthrosis:
a controlled clinical investigation. Curr Med Res Opin 7:104-9, 1980.
52)
Pujalte JM, et al.: Double-blind clinical evaluation of oral glucosamine
sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin
7:110-4, 1980.
53)
Drovanti A, et al.: Therapeutic activity of oral glucosamine sulfate in
osteoarthrosis: a placebo-controlled double-blind investigation. Clin Ther
3:260-72, 1980.
54)D'Ambrosia ED et al.: Glucosamine sulphate: a controlled clinical
investigation in arthrosis. Pharmatherapeutica 2:504-8, 1982.
55)
Vaz AL: Double-blind clinical evaluation of the relative efficacy of
ibuprofen and glucosamine sulfate in the management of osteoarthrosis of the
knee in out-patients. Curr Med Res Opin 8:145-9, 1982.
56)
Muller-Fassbender H, et al.: Glucosamine sulfate compared to ibuprofen in
osteoarthritis of the knee. Osteoarthritis Cartilage 2:61-9, 1994.
57)
Rovati LC, et al.: A large, randomized, placebo controlled, double-blind
study of glucosamine sulfate vs piroxicam and vs their association, on the
kinetics of the symptomatic effect in knee osteoarthritis. Osteoarthritis
Cartilage 2(Suppl.1):56, 1994.
58)
Tapadinhas MJ, et al.: Oral glucosamine sulfate in the management of
arthrosis: report on a multi-centre open investigation in Portugal.
Pharmatherapeutica 3:157-68, 1982.
59)
Sullivan MX and Hess WC: Cystine content of finger nails in arthritis. J
Bone Joint Surg 16:185-8, 1935.
60)
Senturia BD: Results of treatment of chronic arthritis and rheumatoid
conditions with colloidal sulphur. J Bone Joint Surg 16:119-25, 1934.
61) Vignon E, Richard M and Annefeld M: An
in vitro study of glucosamine sulfate on human osteoarthritic cartilage
metabolism. Manuscript in preparation.
62)
Setnikar I, et al.: Pharmacokinetics of glucosamine in man. Arzneim Forsch
43(10):1109-13, 1993.
63) Kelly GS. The Role of Glucosamine Sulfate and
Chondroitin Sulfates in the
Treatment of Degenerative Joint Disease. Altern Med Rev. Feb1998;3(1):27-39.
64) Bourgeois P, Chales G, Dehais J, et al. Efficacy and
tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x
400 mg/day vs placebo. Osteoarthritis Cartilage 1998;6 Suppl A:25-30.
65) Bucsi L, Poor G. Efficacy and tolerability of oral
chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA)
in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998;6
Suppl A:31-36.
66) Cohen M, Wolfe R, Mai T, et al. A randomized, double
blind, placebo controlled trial of a topical cream containing glucosamine
sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J
Rheumatol 2003;30(3):523-528.
67) Conrozier T. [Anti-arthrosis treatments: efficacy and
tolerance of chondroitin sulfates (CS 4&6)]. Presse Med
1998;27(36):1862-1865.
68) Das A, Jr., Hammad TA. Efficacy of a combination of FCHG49
glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin
sulfate and manganese ascorbate in the management of knee osteoarthritis.
Osteoarthritis Cartilage 2000;8(5):343-350.
69) Leeb BF, Petera P, Neumann K. [Results of a multicenter
study of chondroitin sulfate (Condrosulf) use in arthroses of the finger,
knee and hip joints]. Wien Med Wochenschr 1996;146(24):609-614.
70) Leeb BF, Schweitzer H, Montag K, et al. A metaanalysis of
chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol
2000;27(1):205-211.
71) Mazieres B, Loyau G, Menkes CJ, et al. [Chondroitin
sulfate in the treatment of gonarthrosis and coxarthrosis. 5-months result
of a multicenter double-blind controlled prospective study using placebo].
Rev Rhum Mal Osteoartic 1992;59(7-8):466-472.
72) Morreale P, Manopulo R, Galati M, et al. Comparison of the
antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in
patients with knee osteoarthritis. J Rheumatol 1996;23(8):1385-1391.
73) Shankland WE. The effects of glucosamine and chondroitin
sulfate on osteoarthritis of the TMJ: a preliminary report of 50 patients.
Cranio 1998;16(4):230-235.
74) Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent
treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year,
randomized, double-blind, multicenter study versus placebo. Osteoarthritis
Cartilage 2004;12(4):269-276.
75) Van Blitterswijk WJ, Van De Nes JC, Wuisman PI.
Glucosamine and chondroitin sulfate supplementation to treat symptomatic
disc degeneration: Biochemical rationale and case report. BMC Complement
Altern Med 2003;3(1):2.
76) Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD
(structure/disease modifying anti- osteoarthritis drug) in the treatment of
finger joint OA. Osteoarthritis Cartilage 1998;6 Suppl A:37-38.
77) Newnham RE. Essentiality of boron for healthy
bones and joints. Environ Health Perspect. 1994 Nov;102 Suppl 7:83-5.
78)
Rainey CJ, Nyquist LA, Christensen RE, Strong PL, Culver BD, Coughlin JR.
Daily boron intake from the American diet.
J Am Diet Assoc. 1999 Mar;99(3):335-40.
79)
Jacob SW, Appleton J. MSM: The Definitive Guide. A
Comprehensive Review of the Science and Therapeutics of
Methylsulfonylmethane.
Topanga, CA: Freedom Press; 2003:107-121.
80) Leblan D, Chantre P,
Fournie B. Harpagophytum procumbens in the Teatment of Knee and Hip
Osteoarthritis. Four-month Results of a Prospective, Multicenter,
Double-blind Trial Versus Diacerhein. Joint Bone Spine.
2000;67(5):462-7.
81) Qui GX, et al. Efficacy and Safety of Glucosamine Sulfate Versus
Ibuprofen in Patients with Knee Osteoarthritis.
Arzneimittelforschung. May1998;48(5):469-74.
82) Inoue K, Motonaga A, Nishimura T,
Yokota M, Miki N, Fujisawa H, Ueda F, Shibata Y, Kimura K. Mechanism
of anti-inflammatory action of etodolac.
Arzneimittelforschung. 1991 Mar;41(3):235-9.
83) Felton G. Does Kinin released by pineapple stem bromelain
stimulate production of prostaglandin E1-like compound. Haw Med J 1976;2:39-47.
84) Lehto M, Jarvinen M. Collagen and gly-cosaminoglycan
synthesis of injured gastroc-nemius muscle in rat. Eur Surg Res
1985;17:179-185. Cancer. Austin, TX: R.G. Landes Company; 1994:45-52.
85) Zupanets IA, Bezdetko NV, Dedukh NV, Otrishko IA.
Experimental study of the effect of glucosamine hydrochloride on metabolic
and repair processes in connective tissue structures. Eksp Klin Farmakol
2002;65:67-69.
86) Reddy GK, Chandrakasan G, Dhar
SC. Studies on the metabolism of glycosaminoglycans under the influence of
new herbal anti-inflammatory agents. Biochem Pharmacol
1989;38(20):3527-3534.
87) Usha PR, Naidu MUR,
Randomized, double-blind, parallel, placebo-controlled study of oral
glucosamine, methylsulfonylmethane and their combination in osteoarthritis.
Clin Drug Invest. 2004;24:353-363
88)
Dingle JT. The
effects of NSAID on the matrix of human articular cartilages. Addenbrooke's
Hospital, UK-Cambridge.
Z Rheumatol. 1999 Jun;58(3):125-9.
Claims made on this
site have not been evaluated by the United States Food and Drug
Administration and are for informational purposes only and is not intended
as a substitute for advice from your physician or other health care
professional. This product is not intended to diagnose, treat, cure or
prevent disease. Zymosine is a trademark of Boulder Natural Labs, LLC.
|
